Symbols / TRDA Stock $7.00 +2.52% Entrada Therapeutics, Inc.
TRDA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ratings
Current target
$7.00
Low
$10.00
High
$25.00
Mean
$19.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-08 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2026-04-06 | main | Oppenheimer | Outperform → Outperform | $23 |
| 2026-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2026-02-11 | init | Guggenheim | — → Buy | $20 |
| 2025-05-20 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-03-31 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-25 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-04 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-12-05 | init | Roth MKM | — → Buy | $29 |
| 2024-11-06 | main | Oppenheimer | Outperform → Outperform | $28 |
| 2024-11-06 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-08-26 | reit | Oppenheimer | Outperform → Outperform | $25 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-06-25 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-03-18 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-01-05 | init | Oppenheimer | — → Outperform | $22 |
| 2023-11-27 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-09-22 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-08-09 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2023-08-02 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
- $TRDA stock is down 55% today. Here's what we see in our data. - Quiver Quantitative hu, 07 May 2026 14
- Entrada posts early Duchenne benefit, says cash lasts into Q3 2027 - Stock Titan hu, 07 May 2026 11
- Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance hu, 07 May 2026 12
- Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why - Benzinga hu, 07 May 2026 17
- Entrada plunges on trial data for Duchenne drug (TRDA:NASDAQ) - Seeking Alpha hu, 07 May 2026 14
- Market Movers | Winners: BNZI, OLOX, AGL | Losers: GDC, ENGN, TRDA - Trefis Fri, 08 May 2026 03
- Entrada Therapeutics (TRDA) Earnings Date and Reports 2026 $TRDA - MarketBeat Fri, 08 May 2026 07
- Entrada Therapeutics (TRDA) Q1 Revenue Slump Tests High Growth Narratives - simplywall.st Fri, 08 May 2026 00
- Entrada Therapeutics, Inc. (TRDA) Stock Analysis: Exploring A 105.99% Potential Upside - DirectorsTalk Interviews hu, 13 Nov 2025 08
- Duchenne trial readout from Entrada arrives Thursday morning - Stock Titan Wed, 06 May 2026 20
- Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains? - Yahoo Finance ue, 05 May 2026 13
- Duchenne study finds no serious side effects, better Time to Rise - Stock Titan hu, 07 May 2026 11
- Entrada Therapeutics (NASDAQ: TRDA) posts Q1 2026 results and promising Duchenne data - Stock Titan hu, 07 May 2026 11
- [Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan Mon, 04 May 2026 23
- Entrada Therapeutics (NASDAQ: TRDA) widens loss but reports cash runway into 2027 - Stock Titan hu, 07 May 2026 11
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
25.42
-87.94%
|
210.78
+63.38%
|
129.01
|
0.00
|
| Operating Revenue |
|
25.42
-87.94%
|
210.78
+63.38%
|
129.01
|
0.00
|
| Operating Expense |
|
183.32
+11.94%
|
163.77
+23.90%
|
132.18
+35.92%
|
97.25
|
| Research And Development |
|
142.27
+13.54%
|
125.31
+25.45%
|
99.88
+49.96%
|
66.61
|
| Selling General And Administration |
|
41.05
+6.72%
|
38.47
+19.12%
|
32.29
+5.39%
|
30.64
|
| General And Administrative Expense |
|
41.05
+6.72%
|
38.47
+19.12%
|
32.29
+5.39%
|
30.64
|
| Other Gand A |
|
41.05
+6.72%
|
38.47
+19.12%
|
32.29
+5.39%
|
30.64
|
| Total Expenses |
|
183.32
+11.94%
|
163.77
+23.90%
|
132.18
+35.92%
|
97.25
|
| Operating Income |
|
-157.90
-435.87%
|
47.01
+1586.75%
|
-3.16
+96.75%
|
-97.25
|
| Total Operating Income As Reported |
|
-157.90
-435.87%
|
47.01
+1586.75%
|
-3.16
+96.75%
|
-97.25
|
| EBITDA |
|
-153.80
-402.86%
|
50.78
+15920.56%
|
-0.32
+99.66%
|
-95.35
|
| Normalized EBITDA |
|
-153.80
-402.86%
|
50.78
+15920.56%
|
-0.32
+99.66%
|
-95.35
|
| Reconciled Depreciation |
|
4.10
+8.56%
|
3.77
+32.81%
|
2.84
+49.92%
|
1.90
|
| EBIT |
|
-157.90
-435.87%
|
47.01
+1586.75%
|
-3.16
+96.75%
|
-97.25
|
| Net Income |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Pretax Income |
|
-142.83
-314.82%
|
66.48
+451.47%
|
12.06
+112.74%
|
-94.62
|
| Net Non Operating Interest Income Expense |
|
15.07
-22.60%
|
19.47
+27.97%
|
15.22
+478.19%
|
2.63
|
| Net Interest Income |
|
15.07
-22.60%
|
19.47
+27.97%
|
15.22
+478.19%
|
2.63
|
| Interest Income Non Operating |
|
15.07
-22.60%
|
19.47
+27.97%
|
15.22
+478.19%
|
2.63
|
| Interest Income |
|
15.07
-22.60%
|
19.47
+27.97%
|
15.22
+478.19%
|
2.63
|
| Tax Provision |
|
0.92
+7.57%
|
0.86
-95.42%
|
18.74
|
0.00
|
| Tax Rate For Calcs |
|
0.00
+1515.38%
|
0.00
-93.81%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Net Income From Continuing Operation Net Minority Interest |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Net Income From Continuing And Discontinued Operation |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Net Income Continuous Operations |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Normalized Income |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Net Income Common Stockholders |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Diluted EPS |
|
-3.47
-306.55%
|
1.68
+940.00%
|
-0.20
+93.38%
|
-3.02
|
| Basic EPS |
|
-3.47
-297.16%
|
1.76
+980.00%
|
-0.20
+93.38%
|
-3.02
|
| Basic Average Shares |
|
41.37
+10.90%
|
37.31
+12.88%
|
33.05
+5.61%
|
31.29
|
| Diluted Average Shares |
|
41.37
+6.07%
|
39.00
+18.01%
|
33.05
+5.61%
|
31.29
|
| Diluted NI Availto Com Stockholders |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-2.63
|
| Line Item | Trend | 2021-12-31 |
|---|---|---|
| Total Assets |
|
—
|
| Current Assets |
|
—
|
| Cash Cash Equivalents And Short Term Investments |
|
—
|
| Cash And Cash Equivalents |
|
—
|
| Cash Equivalents |
|
—
|
| Cash Financial |
|
—
|
| Other Short Term Investments |
|
—
|
| Receivables |
|
—
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
7.64
|
| Restricted Cash |
|
—
|
| Other Current Assets |
|
—
|
| Total Non Current Assets |
|
—
|
| Net PPE |
|
—
|
| Gross PPE |
|
—
|
| Accumulated Depreciation |
|
—
|
| Properties |
|
—
|
| Machinery Furniture Equipment |
|
—
|
| Construction In Progress |
|
0.00
|
| Other Properties |
|
—
|
| Leases |
|
—
|
| Other Non Current Assets |
|
—
|
| Total Liabilities Net Minority Interest |
|
—
|
| Current Liabilities |
|
—
|
| Payables And Accrued Expenses |
|
—
|
| Payables |
|
—
|
| Accounts Payable |
|
—
|
| Current Accrued Expenses |
|
—
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
—
|
| Total Tax Payable |
|
—
|
| Income Tax Payable |
|
—
|
| Current Debt And Capital Lease Obligation |
|
—
|
| Current Capital Lease Obligation |
|
—
|
| Current Deferred Liabilities |
|
—
|
| Current Deferred Revenue |
|
—
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
| Long Term Capital Lease Obligation |
|
—
|
| Non Current Deferred Liabilities |
|
—
|
| Non Current Deferred Revenue |
|
—
|
| Stockholders Equity |
|
—
|
| Common Stock Equity |
|
—
|
| Capital Stock |
|
—
|
| Common Stock |
|
—
|
| Share Issued |
|
—
|
| Ordinary Shares Number |
|
—
|
| Treasury Shares Number |
|
0.11
|
| Additional Paid In Capital |
|
—
|
| Retained Earnings |
|
—
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
| Other Equity Adjustments |
|
—
|
| Total Equity Gross Minority Interest |
|
—
|
| Total Capitalization |
|
—
|
| Working Capital |
|
—
|
| Invested Capital |
|
—
|
| Total Debt |
|
—
|
| Capital Lease Obligations |
|
—
|
| Net Tangible Assets |
|
—
|
| Tangible Book Value |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-128.51
-209.24%
|
-41.56
-129.73%
|
139.80
+249.07%
|
-93.79
|
| Cash Flow From Continuing Operating Activities |
|
-128.51
-209.24%
|
-41.56
-129.73%
|
139.80
+249.07%
|
-93.79
|
| Net Income From Continuing Operations |
|
-143.75
-319.04%
|
65.63
+1081.69%
|
-6.68
+92.93%
|
-94.62
|
| Depreciation Amortization Depletion |
|
4.10
+8.56%
|
3.77
+32.81%
|
2.84
+49.92%
|
1.90
|
| Depreciation |
|
4.10
+8.56%
|
3.77
+32.81%
|
2.84
+49.92%
|
1.90
|
| Depreciation And Amortization |
|
4.10
+8.56%
|
3.77
+32.81%
|
2.84
+49.92%
|
1.90
|
| Stock Based Compensation |
|
19.61
+9.46%
|
17.91
+36.64%
|
13.11
+32.50%
|
9.89
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
-4.80
+95.96%
|
-118.85
-187.19%
|
136.31
+1326.85%
|
-11.11
|
| Change In Receivables |
|
2.50
+13.88%
|
2.20
+137.39%
|
-5.88
|
0.00
|
| Change In Prepaid Assets |
|
7.64
+272.23%
|
-4.44
-151.46%
|
8.62
+161.49%
|
-14.02
|
| Change In Payables And Accrued Expense |
|
2.28
+445.90%
|
-0.66
-113.08%
|
5.03
-28.63%
|
7.05
|
| Change In Accrued Expense |
|
4.74
+177.63%
|
1.71
-55.19%
|
3.81
+116.35%
|
1.76
|
| Change In Payable |
|
-2.47
-4.23%
|
-2.37
-294.09%
|
1.22
-76.94%
|
5.29
|
| Change In Account Payable |
|
-1.80
-281.53%
|
0.99
+135.33%
|
-2.81
-153.05%
|
5.29
|
| Change In Other Working Capital |
|
-19.82
+83.45%
|
-119.81
-185.59%
|
139.98
|
—
|
| Change In Other Current Assets |
|
10.88
-15.48%
|
12.88
+2922.54%
|
0.43
-87.14%
|
3.31
|
| Change In Other Current Liabilities |
|
-8.28
+8.29%
|
-9.02
+23.93%
|
-11.86
-59.20%
|
-7.45
|
| Investing Cash Flow |
|
116.81
+520.20%
|
-27.80
+79.91%
|
-138.40
+6.90%
|
-148.65
|
| Cash Flow From Continuing Investing Activities |
|
116.81
+520.20%
|
-27.80
+79.91%
|
-138.40
+6.90%
|
-148.65
|
| Net PPE Purchase And Sale |
|
-1.04
+67.04%
|
-3.16
+43.75%
|
-5.61
-94.46%
|
-2.89
|
| Purchase Of PPE |
|
-1.04
+67.04%
|
-3.16
+43.75%
|
-5.61
-94.46%
|
-2.89
|
| Capital Expenditure |
|
-1.04
+67.04%
|
-3.16
+43.75%
|
-5.61
-94.46%
|
-2.89
|
| Net Investment Purchase And Sale |
|
117.85
+578.28%
|
-24.64
+81.44%
|
-132.78
+8.91%
|
-145.76
|
| Purchase Of Investment |
|
-141.61
+67.65%
|
-437.72
-7.49%
|
-407.21
-83.45%
|
-221.98
|
| Sale Of Investment |
|
259.46
-37.19%
|
413.08
+50.52%
|
274.43
+260.07%
|
76.21
|
| Financing Cash Flow |
|
0.89
-99.14%
|
102.96
+389.44%
|
21.04
+4291.86%
|
0.48
|
| Cash Flow From Continuing Financing Activities |
|
0.89
-99.14%
|
102.96
+389.44%
|
21.04
+4291.86%
|
0.48
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
99.61
+413.26%
|
19.41
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.89
-73.57%
|
3.36
+105.89%
|
1.63
+240.29%
|
0.48
|
| Changes In Cash |
|
-10.82
-132.18%
|
33.61
+49.74%
|
22.45
+109.28%
|
-241.96
|
| Beginning Cash Position |
|
105.16
+46.97%
|
71.55
+45.71%
|
49.11
-83.13%
|
291.06
|
| End Cash Position |
|
94.34
-10.29%
|
105.16
+46.97%
|
71.55
+45.71%
|
49.11
|
| Free Cash Flow |
|
-129.55
-189.73%
|
-44.72
-133.32%
|
134.19
+238.81%
|
-96.67
|
| Income Tax Paid Supplemental Data |
|
1.70
-63.24%
|
4.62
-68.59%
|
14.72
|
0.00
|
| Amortization Of Securities |
|
-3.67
+63.36%
|
-10.02
-73.35%
|
-5.78
-3927.15%
|
0.15
|
| Change In Income Tax Payable |
|
-0.67
+80.13%
|
-3.36
-183.42%
|
4.02
|
0.00
|
| Change In Tax Payable |
|
-0.67
+80.13%
|
-3.36
-183.42%
|
4.02
|
0.00
|
| Common Stock Issuance |
|
0.00
-100.00%
|
99.61
+413.26%
|
19.41
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
99.61
+413.26%
|
19.41
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-07 View
- 8-K2026-05-07 View
- 42026-05-04 View
- 42026-05-04 View
- 42026-04-02 View
- 42026-03-11 View
- 42026-03-11 View
- 42026-03-06 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 10-K2026-02-26 View
- 8-K2026-02-26 View
- 8-K2026-01-08 View
- 42025-11-24 View
- 42025-11-24 View
- 42025-11-18 View
- 42025-11-18 View
- 42025-11-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|